Home › Trials › NCT07234162

Golidocitinib versus physician-selected therapy for relapsed/refractory peripheral T‑cell lymphoma (Phase 3 JACKPOT19)

A Phase 3, Open-Label, Randomized, Multinational Study to Investigate the Anti-tumor Efficacy of Golidocitinib Versus Investigator's Choice in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma

Phase 3 Interventional Dizal Pharmaceuticals · NCT07234162

This Phase 3 test compares golidocitinib with treatments chosen by a doctor to see if it better controls disease in adults with relapsed or refractory peripheral T‑cell lymphoma.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment218 (estimated)
Ages18 Years and up
SexAll
SponsorDizal Pharmaceuticals Industry-sponsored
Drugs / interventionsgolidocitinib
Locations50 sites (Hefei, Anhui and 49 other locations)
Trial IDNCT07234162 on ClinicalTrials.gov

What this trial studies

This is a randomized, open‑label Phase 3 trial that compares the oral agent golidocitinib to investigator‑chosen chemotherapy or targeted agents in adults with relapsed or refractory peripheral T‑cell lymphoma (PTCL). Eligible patients must have histologically confirmed PTCL of specified subtypes and have progressed on, been refractory to, or been intolerant of at least one prior systemic therapy. Participants are randomized to receive golidocitinib or one of several physician‑selected options such as chidamide, pralatrexate, gemcitabine, or belinostat. The study uses standard anti‑tumor efficacy and disease‑control endpoints to determine whether golidocitinib provides improved clinical benefit.

Who should consider this trial

Good fit: Adults aged 18 or older with histologically confirmed PTCL of the eligible subtypes who have relapsed after, been refractory to, or are intolerant of at least one prior systemic regimen, with ECOG performance status 0–2 and life expectancy of at least 12 weeks, are ideal candidates.

Not a fit: Patients with newly diagnosed disease, non‑eligible lymphoma subtypes, ECOG >2, life expectancy under 12 weeks, or those unable to receive the protocol therapies are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, golidocitinib could offer a more effective treatment option that improves response rates or delays disease progression for patients with relapsed or refractory PTCL.

How similar studies have performed: Some earlier‑phase studies of targeted agents and HDAC inhibitors have shown activity in PTCL, but randomized Phase 3 evidence comparing new agents to physician‑chosen options is limited.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* The participants should sign the ICF and be able to comply with the relevant requirement in the ICF and protocol
* Age ≥ 18 years
* ECOG 0-2 score, life expectancy ≥ 12 weeks
* Patients must have histologically confirmed peripheral T-cell lymphoma according to the World Health Organization classification of lymphoma. Eligible subtypes are restricted to: PTCL-not otherwise specified, NOS (PTCL, NOS), Angioimmunoblastic T-cell lymphoma (AITL), anaplastic large-cell lymphoma ALK-positive (ALCL ALK+), anaplastic large-cell lymphoma ALK-negative (ALCL ALK-), Follicular T-cell lymphoma, or PTCL with T-follicular helper (TFH) phenotype (FTCL or PTCL-TFH), Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), Natural killer/T-cell lymphoma (NK/TCL), Hepatosplenic T-cell lymphoma (HSTCL), Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)
* Progressed on, were refractory to or intolerant to at least one line of prior standard systemic therapies assessed by investigator
* Adequate bone marrow reserve and organ system functions
* Willing to comply with contraceptive restrictions

Exclusion Criteria:

* Any of previous or current treatment prohibited by protocol
* Any unresolved \> grade 2 drug-related adverse events
* Lymphoma involving central nervous system
* Any of serere cardiac or pulmonary abnormalities
* Disease condition requiring immunosuppressants, biologics, or NSAIDs
* Active infection
* Malignancy disease within five years
* Poorly controlled gastrointestinal disorder or inadequate absorption of medication
* Severe or poorly controlled systemic diseases

Where this trial is running

Hefei, Anhui and 49 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Peripheral T-cell Lymphoma
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.